
Quarterly report 2022-Q1
added 12-23-2023
Natus Medical Incorporated Net Debt 2011-2026 | NTUS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Natus Medical Incorporated
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -64.1 M | -69.5 M | -37.8 M | 48.1 M | 65.3 M | -39.5 M | -82.5 M | -66.6 M | -18.1 M | 9.8 M | -31.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.3 M | -82.5 M | -26.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.07 | 0.33 % | $ 1.63 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
-925 M | $ 171.87 | 0.74 % | $ 12.9 B | ||
|
AxoGen
AXGN
|
15.2 M | $ 32.64 | -5.23 % | $ 1.5 B | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 4.13 | 0.49 % | $ 874 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 36.74 | -0.05 % | $ 5.47 K | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 62.59 | -0.37 % | $ 92.7 B | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 10.97 | 1.29 % | $ 1.65 B | ||
|
CONMED Corporation
CNMD
|
802 M | - | - | $ 1.06 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 9.38 | 0.11 % | $ 266 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.59 | 1.2 % | $ 36.7 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 9.7 | 0.73 % | $ 347 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 81.19 | 0.17 % | $ 47.5 B | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 23.61 | 1.37 % | $ 200 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.6 | 0.05 % | $ 122 M | ||
|
Globus Medical
GMED
|
-511 M | $ 88.6 | 0.77 % | $ 12 B | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.9 | 2.15 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
-86.3 M | $ 6.36 | 2.42 % | $ 169 M | ||
|
Inspire Medical Systems
INSP
|
-433 M | $ 54.14 | -1.55 % | $ 1.59 B | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.0 | 1.66 % | $ 16.9 M | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 95.66 | -0.59 % | $ 1.22 B | ||
|
Integer Holdings Corporation
ITGR
|
1.18 B | $ 85.63 | -1.4 % | $ 2.97 B | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M |